路易体痴呆症中阿尔茨海默病生物标志物的体内流行率。
In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies.
机构信息
Unit of Neurochemistry and Biological Markers, First Department of Neurology, Eginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece,
Unit of Neurochemistry and Biological Markers, First Department of Neurology, Eginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Dement Geriatr Cogn Disord. 2019;47(4-6):289-296. doi: 10.1159/000500567. Epub 2019 Jul 16.
BACKGROUND
Neuropathological studies indicate concomitant Alzheimer's disease (AD) pathology in patients with dementia with Lewy bodies (DLB).
OBJECTIVES
To measure cerebrospinal fluid (CSF) levels of β-amyloid peptide with 42 amino acids (Aβ42), total tau protein (τT), and tau phosphorylated at threonine 181 (τP-181) in 38 patients fulfilling the diagnostic criteria of probable DLB according to the most recent (4th consensus) report.
METHODS
Double-sandwich commercial ELISAs (Innotest; Fujirebio, Gent, Belgium) were used for measurements.
RESULTS
According to the current cutoff values of our laboratory, 4 biomarker profiles were noted: abnormal levels of Aβ42 only (44.7%), full AD profile (39.5%), abnormal levels of τT only (5.3%), and normal levels of all 3 biomarkers (10.5%). AD profile was associated with female sex, older age, lower education, and lower MMSE scores.
CONCLUSIONS
Reduction in Αβ42 in DLB may be more common (>80% of patients) than previously thought, and ∼40% may have the typical CSF AD biomarker profile. AD biochemistry in DLB may be an evolving process showing increasing frequency with disease progression.
背景
神经病理学研究表明，路易体痴呆（DLB）患者伴有阿尔茨海默病（AD）病理。
目的
根据最近（第 4 次共识报告）的诊断标准，测量 38 例符合可能的 DLB 诊断标准的患者的脑脊液（CSF）中β-淀粉样肽 42 个氨基酸（Aβ42）、总tau 蛋白（τT）和在苏氨酸 181 位磷酸化的 tau（τP-181）的水平。
方法
使用双夹心商业 ELISA（Innotest；Fujirebio，Gent，比利时）进行测量。
结果
根据我们实验室目前的临界值，有 4 种生物标志物谱：仅 Aβ42 水平异常（44.7%）、完整的 AD 谱（39.5%）、仅 τT 水平异常（5.3%）和所有 3 种生物标志物水平正常（10.5%）。AD 谱与女性、年龄较大、教育程度较低和 MMSE 评分较低有关。
结论
DLB 中 Αβ42 的减少可能比以前认为的更常见（超过 80%的患者），约 40%的患者可能具有典型的 CSF AD 生物标志物谱。DLB 中的 AD 生物化学可能是一个不断发展的过程，随着疾病的进展，其出现的频率会增加。
Zotero 插件